



Contact: Tricia J. Richardson  
Novavax, Inc.  
240-268-2031

## **NOVAVAX to Present at Oppenheimer 20<sup>th</sup> Annual Healthcare Conference**

**ROCKVILLE, MD** (October 29, 2009) – /PRNewswire-FirstCall/ - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20<sup>th</sup> Annual Healthcare Conference. Dr. Singhvi's presentation will take place at 3:20 pm local time on November 3, 2009 at the Waldorf=Astoria, New York, NY. Dr. Singhvi will provide an overview of the company's business strategy and research and development progress. A link to the live presentation can be accessed via the Company website at [www.novavax.com](http://www.novavax.com) under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

### **About the Oppenheimer 20<sup>th</sup> Annual Healthcare Conference**

The Oppenheimer 20<sup>th</sup> Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, November 3-4, 2009. This conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders.

The Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.

### **About Novavax**

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: [www.novavax.com](http://www.novavax.com)

###